Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US

By afschroeder • August 5, 2025

Pei PP, Jones M, Hu R, Chen W, Sax PE, Pandya A, Gandhi M, Eron JJ, Currier JS, Wilkin TJ, Reddy KP, Qoshe L, Hyle EP, Freedberg KA. Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US. Clin Infect Dis. 2025 Aug 4:ciaf428. doi: 10.1093/cid/ciaf428. Epub ahead of print. PMID: 40757869.

Tags: clinical trials, HIV, Implementation, Infectious Diseases, long-acting antiretrovirals, Publications, resistance

Related Posts

Healthcare provider and health system leader perspectives on barriers to hypertension care in Malawi: insights from integrated and non-integrated HIV care settings

Hagstrom C, Kalande P, Aryal A, Phiri K, van Oosterhout JJ, Talama G, Lungu E, Phiri S, Moucheraud C, Hoffman R. Healthcare provider and health[...]

Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2–LTR Circles Over 12 Weeks

Reed JC, Hall L, McKhann A, Kwak G, Goecker EA, Coombs RW, Chen H, Roa J, Vecchio A, Daar ES, Hunt PW, Marra CM, Campbell[...]

Author Correction: Barcoded HIV-1 reveals viral persistence driven by clonal proliferation and distinct epigenetic patterns

Zhang TH, Shi Y, Komarova NL, Wodarz D, Kostelny M, Gonzales A, Abbaali I, Chen H, Bresson-Tan G, Dimapasoc M, Harvey W, Oh C, Carmona[...]